Cannabis News
The Marijuana Misinformation Machine – How Politicians Plan to Block Cannabis Legalization
In recent years, we’ve heard politicians clamoring about the dangers of “misinformation” and “disinformation,” with some even calling for regulations on free speech. But these same politicians seem to have a glaring blind spot when it comes to their own history of spreading falsehoods, particularly regarding cannabis.
For over a century, the U.S. government has been the primary purveyor of marijuana misinformation, running smear campaigns that have shaped public perception and policy. From outlandish claims about cannabis-induced insanity in the 1920s to Nixon’s war on drugs in the 1970s, official channels have consistently peddled propaganda over facts.
The irony is palpable. While decrying the spread of misinformation in the digital age, many politicians conveniently ignore the government’s long-standing role as the chief architect of cannabis myths and misconceptions.
Today, we’re diving into this rich history of government-sponsored cannabis disinformation and examining recent findings from the National Institutes of Health (NIH) that reveal a telling trend: Americans don’t trust official sources when it comes to marijuana information.
As we peel back the layers of propaganda and explore the roots of public mistrust, we’ll see how the government’s own actions have undermined its credibility on this issue. The marijuana misinformation machine has been running for decades, and it’s time to set the record straight.
So buckle up, dear readers. We’re about to embark on a journey through the smoky haze of cannabis history, separating fact from fiction and exposing the hypocrisy at the heart of the war on drugs. Let’s dive in!
In an era where information is at our fingertips, it’s ironic that when it comes to cannabis, Americans are turning away from traditional sources of medical knowledge. A recent study published in the Journal of Cannabis Research, partially funded by the National Institute on Drug Abuse, has shed light on this phenomenon, revealing a startling lack of trust in government and medical sources for cannabis information.
The study, which surveyed 1,161 adults nationwide, found that only 4.7% of respondents relied on government agencies for cannabis-related information. Even more surprisingly, health and medical care providers fared only slightly better at 9.3%. Instead, the majority of people turn to friends and family (35.6%) or websites (33.7%) for their cannabis knowledge.
This mistrust isn’t unfounded. For decades, the U.S. government has been the primary purveyor of cannabis misinformation, running smear campaigns that have shaped public perception and policy. This propaganda has not only affected the general public but has also seeped into medical education, creating a knowledge gap among healthcare providers.
The study highlights this medical ignorance, noting that only 9% of medical schools in 2016 offered cannabis-specific curricula. This lack of education isn’t necessarily the fault of individual healthcare providers, but rather a systemic issue rooted in years of government-sponsored misinformation. Many medical professionals simply haven’t had the opportunity to update their “firmware” on the subject matter.
As cannabis use continues to rise and legalization spreads across the country, it’s clear that the medical community needs to catch up. The study authors emphasize the “strong need for better clinician education, public outreach strategies, and improved communication between patients and clinicians about cannabis.”
However, addressing this knowledge gap isn’t as simple as updating medical textbooks. A separate study published in PeerJ Life & Environment reveals a troubling trend in biomedical education materials. The study found that many authors of influential medical textbooks have undisclosed financial conflicts of interest, including patents and compensation from pharmaceutical companies.
This ethical conflict of interest raises questions about the objectivity of medical education materials, particularly when it comes to topics like cannabis that could potentially threaten pharmaceutical profits. As we push for better cannabis education in medical schools, we must also address these underlying conflicts of interest to ensure that future healthcare providers receive unbiased, evidence-based information.
The age of mistrust in official sources of cannabis information presents both challenges and opportunities. While it’s concerning that so few people turn to medical professionals for guidance, it also highlights the need for a major overhaul in how we educate both the public and healthcare providers about cannabis.
As we move forward, it’s crucial that we address the legacy of misinformation, update medical curricula, and ensure transparency in medical education materials. Only then can we hope to bridge the trust gap and provide accurate, unbiased information about cannabis to those who need it most.
The prohibition of cannabis in the United States is a tale woven with threads of deception, racism, and political manipulation. From its inception, the campaign against marijuana has relied on sensationalism and outright lies to justify its existence.
As NORML points out, the initial push for cannabis criminalization had little to do with public health or safety. Instead, it was fueled by xenophobia and racist rhetoric. A prime example is a 1927 New York Times story headlined “Mexican Family Goes Insane,” which farcically claimed that a widow and her children were driven insane by eating the “marihuana plant.” Such sensationalist reporting was common, with a 1933 academic paper in The Journal of Law and Criminology asserting that marijuana use inevitably resulted in “incurable” insanity and death.
At the forefront of this misinformation campaign was Harry J. Anslinger, America’s first “Drug Czar.” Anslinger successfully lobbied Congress to ban cannabis nationwide in 1937, relying heavily on racist rhetoric. He claimed, “There are 100,000 total marijuana smokers in the U.S., and most are Negroes, Hispanics, Filipinos, and entertainers.” He even went so far as to assert that marijuana caused “white women to seek sexual relations with Negroes, entertainers, and any others.”
The weaponization of cannabis misinformation reached new heights during the Nixon administration. Despite privately acknowledging that cannabis wasn’t “particularly dangerous,” Nixon and his team publicly doubled down on the supposed marijuana threat for political gain. John Ehrlichman, Nixon’s domestic policy chief, later admitted the true motives behind their actions: “We couldn’t make it illegal to be either against the (Vietnam) war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin… we could disrupt those communities.”
This legacy of lies continued well into the late 20th century with programs like D.A.R.E. (Drug Abuse Resistance Education), which perpetuated exaggerated claims about marijuana. The “lazy stoner” stereotype, heavily promoted by these campaigns, has been debunked by recent studies showing that cannabis users tend to be more active than their non-using counterparts.
Given this extensive history of deception, is it any wonder that people don’t trust the government on cannabis-related information? The federal government didn’t just create fake studies; they actively stonewalled legitimate research to sustain a policy founded on lies and misinformation. This deliberate suppression of scientific inquiry has had far-reaching consequences, hindering our understanding of cannabis and its potential benefits for decades.
The damage caused by this misinformation campaign extends beyond public perception. It has shaped policy, driven mass incarceration, and stifled potentially life-changing medical research. The classification of cannabis as a Schedule I substance, alongside drugs like heroin, flies in the face of scientific evidence and has been a major obstacle to comprehensive study.
This is why simply rescheduling cannabis is not enough. What we need is a complete dismantling of the Controlled Substances Act (CSA). We need an independent, unbiased group to research these substances without the weight of decades of political baggage. It’s time to rethink our approach as a society to drug consumption and remove the regulatory hurdles that have long impeded research and product development.
The path forward requires more than just correcting misinformation; it demands a fundamental shift in how we approach drug policy. We must acknowledge the racist and politically motivated roots of cannabis prohibition and work to undo the harm caused by decades of lies. Only then can we hope to develop a rational, evidence-based approach to cannabis that prioritizes public health, individual liberty, and scientific truth over political agendas and corporate interests.
As we move into a new era of cannabis policy, let’s learn from the mistakes of the past. It’s time to replace fear-mongering with facts, propaganda with peer-reviewed research, and prohibition with sensible regulation. The history of cannabis prohibition in America is indeed a history of lies – but it doesn’t have to be our future.
After more than half a century of lies, misinformation, and propaganda, the U.S. government and healthcare establishment face a monumental task: regaining the public’s trust on cannabis and drug policy. But here’s the harsh truth – they can’t. At least, not without radical, systemic change.
The problem runs deep. How can we trust pharma-sponsored studies when there’s an obvious conflict of interest? How can we believe government agencies that have consistently prioritized political agendas over scientific truth? The credibility well has run dry, and refilling it will require more than just a change in rhetoric or policy tweaks.
The only path forward is a complete overhaul of our approach to drugs in America. This means dismantling the Controlled Substances Act (CSA) and renegotiating how we produce, distribute, and regulate drugs in the U.S. Until we take this drastic step, public trust in government agencies and healthcare providers on these issues will remain – justifiably – at rock bottom.
We need to create a new system built on transparency, scientific integrity, and genuine concern for public health. This means severing the ties between drug policy and corporate interests, political agendas, and law enforcement quotas. It means funding independent research, free from the influence of pharmaceutical companies or government agencies with a vested interest in maintaining the status quo.
Let’s be clear: you can’t trust a politician who takes money from Big Pharma or law enforcement unions to make unbiased decisions about drug legalization. That’s like trusting an obese person’s advice on losing weight – the conflict of interest is too glaring to ignore.
Moving forward, we need to demand full transparency in medical education, research funding, and policy-making. We need to elevate voices that have been historically marginalized in these discussions, including those of cannabis users, medical patients, and communities disproportionately affected by the war on drugs.
The road to rebuilding trust will be long and challenging. But it starts with acknowledging past wrongs, committing to radical change, and putting the wellbeing of individuals and communities above political and corporate interests. Only then can we hope to create a drug policy that truly serves the American people.
SOURCES:
MISINFORMATION IN YOUR FEED, YOU BET, READ ON…
For decades, veterans and civilians alike have turned to cannabis to manage their PTSD symptoms, often finding relief where traditional pharmaceuticals fell short. Walk into any VA hospital, and you’ll likely find patients being prescribed a cocktail of medications – SSRIs like sertraline and paroxetine, anti-anxiety drugs like alprazolam, sleep aids like zolpidem, and sometimes even antipsychotics. Yet many vets report these medications leave them feeling like zombies, trading one set of problems for another.
As someone who’s been following cannabis policy for years, I’ve watched countless researchers bang their heads against the wall trying to study this plant’s potential for PTSD treatment. The roadblocks have been numerous and, frankly, ridiculous. Despite overwhelming anecdotal evidence and desperate pleas from the veteran community, getting approval for clinical trials involving smokable cannabis has been about as easy as teaching a cat to swim – theoretically possible, but practically impossible.
That’s why the FDA’s recent approval of a landmark clinical trial has caught my attention. After three years of back-and-forth negotiations, the Multidisciplinary Association for Psychedelic Studies (MAPS) finally got the green light to conduct a Phase 2 study examining smoked cannabis for PTSD in veterans. This isn’t just another sterile laboratory experiment – it’s designed to reflect real-world usage patterns, something we’ve desperately needed in cannabis research.
In this article, we’ll dive deep into what this study means for veterans, the cannabis community, and the future of federal legalization. We’ll explore why this research is groundbreaking, how it might reshape our understanding of cannabis as medicine, and what it could mean for the millions of Americans living with PTSD.
Let’s dive into what makes this study so groundbreaking. MAPS isn’t just dipping their toes in the water – they’re diving in headfirst with a comprehensive Phase 2 clinical trial involving 320 veterans suffering from moderate to severe PTSD. What makes this study particularly fascinating is its focus on “real-world” cannabis use, allowing participants to self-titrate their dosage of high-THC flower within certain limits.
Now, for those who aren’t familiar with the FDA’s clinical trial phases, let me break it down. Phase 1 typically focuses on safety and involves a small group of people. Phase 2 – where this study sits – is where things get interesting. It’s designed to test both effectiveness and side effects, involving a larger group of participants. If successful, Phase 3 would follow with an even larger group, and finally, Phase 4 would monitor long-term safety after FDA approval.
The fact that this study reached Phase 2 is a big deal, folks. It means we’ve cleared the initial safety hurdles and are moving into territory that could actually influence medical policy. But what really sets this research apart is its focus on smokable flower. This wasn’t an easy win – MAPS had to fight through five partial clinical hold letters from the FDA just to get here.
Why does the smoking aspect matter so much? Well, think about it – most FDA-approved medications come in neat little pills or carefully measured doses. Smoking cannabis? That’s been a major sticking point for regulatory agencies. By including smoking as a delivery method, this study acknowledges how most veterans actually use cannabis in the real world. No fancy pharmaceutical extracts or synthetic compounds – just the plant in its most basic, smokable form.
The implications here are huge. If this study demonstrates positive results, it could fundamentally change how we approach cannabis as medicine. It might force regulatory bodies to reconsider their stance on smokable cannabis, potentially opening doors for more research and eventual federal approval of whole-plant medicine. This could be particularly significant for veterans, who often prefer smoking or vaping cannabis for its rapid onset and ease of dose control.
But perhaps most importantly, this study could provide the hard scientific evidence we’ve been missing. While thousands of veterans have testified about cannabis helping their PTSD, the lack of controlled clinical trials has been a major roadblock in changing federal policy. A successful outcome here could be the wedge we need to finally crack open the door to federal legalization.
Of course, we shouldn’t count our chickens before they hatch. Clinical trials are complex beasts, and there’s still a long road ahead. But for the first time in a long while, I’m feeling optimistic about the direction we’re heading. This study could be the game-changer we’ve been waiting for in the fight for cannabis legitimacy.
Let’s talk about PTSD – a condition that affects roughly 12 million American adults annually. That’s more people than the entire population of New York City, folks. Post-Traumatic Stress Disorder isn’t just about being scared or anxious; it’s a complex psychological condition where traumatic experiences get stuck in an endless replay loop, like a scratched record that keeps skipping back to the same devastating track.
But here’s where cannabis enters the picture, and it’s fascinating how it works. Our endocannabinoid system plays a crucial role in how we process and store memories, particularly emotional ones. When someone consumes cannabis, it can help disrupt those stubborn neural pathways that keep trauma loops running. Think of it like hitting the pause button on a horror movie that’s been playing on repeat in someone’s head.
However – and this is crucial – cannabis isn’t a magic eraser for trauma. I’ve spoken with countless veterans who use cannabis, and they’re the first to tell you: the plant helps manage symptoms, but it doesn’t “cure” PTSD. Real healing requires doing the hard work of processing and integrating traumatic experiences. Cannabis is more like a helpful companion on that journey rather than the destination itself.
What makes cannabis particularly interesting in PTSD treatment is its ability to increase neuroplasticity – the brain’s ability to form new neural connections and reorganize existing ones. This is where the real magic happens. When someone’s brain becomes more “plastic,” they’re better equipped to process traumatic memories and potentially create new, healthier neural pathways.
Speaking of neuroplasticity, we can’t ignore the elephant in the room – psilocybin. Recent studies have shown remarkable promise in treating PTSD with psilocybin-assisted therapy, often producing profound and lasting changes in just a few sessions. The fact that both cannabis and psilocybin increase neuroplasticity while offering different therapeutic approaches suggests we might be onto something big in trauma treatment.
What drives me crazy is how long it’s taken to get here. We’ve known about cannabis’s potential benefits for PTSD for decades. Veterans have been telling us. Trauma survivors have been telling us. Heck, even some forward-thinking psychiatrists have been telling us. Yet we’re only now getting around to serious clinical research? It’s a testament to how prohibition hasn’t just restricted access to cannabis – it’s actively delayed our understanding of this plant’s therapeutic potential.
But hey, better late than never, right? As we move forward with studies like the MAPS trial, we’re finally starting to piece together the scientific puzzle that veterans and other PTSD survivors have known about all along. Cannabis isn’t just helping them sleep better or feel calmer – it’s potentially giving them the neurological flexibility they need to process and integrate their trauma in a healthy way.
Like most things in the cannabis reform movement, progress moves at a snail’s pace. But as frustrating as it might be, we’re undeniably moving forward. The FDA’s approval of this MAPS study, focusing on smokable cannabis no less, marks a significant shift in how our regulatory bodies view cannabis research.
The beauty of this study lies in its real-world approach. No artificial laboratory settings or synthetic cannabinoids – just veterans using cannabis the way they already do. This authenticity could provide invaluable data about how cannabis actually functions as a medicine in everyday life, not just in theory.
Let’s be real though – regardless of what this study finds, veterans and others suffering from PTSD who’ve found relief with cannabis aren’t going to stop using it. The plant has been their lifeline when traditional pharmaceuticals failed them. But positive findings could open doors for countless others who might benefit from cannabis but have been hesitant due to its federal status or lack of clinical validation.
This is particularly crucial for our veteran community. With veteran suicide rates remaining tragically high – averaging around 17 deaths per day – we desperately need more treatment options. It’s no coincidence that veteran groups have been among the loudest voices calling for cannabis research and reform. They’ve seen firsthand how this plant can offer hope where traditional treatments have fallen short.
As we await the results of this groundbreaking study, I remain cautiously optimistic. Sure, progress is slower than we’d like, but each step forward brings us closer to a future where veterans and others with PTSD can access the medicine they need without stigma or legal barriers. And for the countless individuals struggling with PTSD, that future can’t come soon enough.
Source:
www.marijuanamoment.net/fda-approves-long-awaited-clinical-trial-of-smoked-marijuana-to-treat-ptsd-in-veterans/
ARE PSYCHEDELICS JUST WEED 2.0? READ ON…
ARE MAGIC MUSHROOMS THE NEW WEED 2.0? WE ASKED THE EXPERTS!
Who is the cannabis breeder Barney’s Farm?
Veterans With PTSD Are Given A Little Hope
FDA Approves Landmark Clinical Trial for Veterans with PTSD and Smoking Cannabis
Oregon Cannabis: Get Your OLCC Renewal or New Application in Before December 5th
How Organic Hemp Rolling Papers Affect the Flavor and Smoking Experience
Emerald’s 2024 Holiday Gift Guide
What Your Method of Cannabis Consumption Says About you
DEA Hearings – Yesterday’s (12/2/2024) Livestream – 1:36
Keep it Lowkey with Discreet Cannabis Products
Can CBD Keep Cats From The Christmas Tree
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
-
Cannabis News2 years agoDistressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years agoUnited States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years agoWhat you Need to Know
-
drug testing12 months agoDrug Testing for Marijuana – The Joint Blog
-
Education2 years agoNCIA Write About Their Equity Scholarship Program
-
Cannabis2 years agoIt has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years agoCannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years agoA new April 20 cannabis contest includes a $40,000 purse